The Regenerative Medicine Annual Report, released today at the Alliance for Regenerative Medicine's (ARM) first annual Regen Med Investor Day, provides an overview of the tremendous growth and progress in the regenerative medicine (RM) sector during the past year.
Regenerative medicine company, Regeneus, has established a new cell processing laboratory at John Flynn Private Hospital in the Gold Coast which will allow registered medical specialists to treat their patients with HiQCell®, an innovative stem cell therapy for musculoskeletal conditions.
Regenerative medicine company, Regeneus, is pleased to announce that Provet, the largest veterinary distribution company in Australia, has been appointed to distribute CryoShot®, the company’s proprietary “off-the-shelf” stem cell therapy for the treatment of musculoskeletal disorders in dogs and horses. This is the first stem cell therapy product distributed by Provet in Australia.
Regenerative medicine company, Regeneus, and researchers at the Kolling Institute of Medical Research, have discovered in preliminary findings that Regeneus prepared stem cells have a positive improvement on the effect of a cell-based cancer treatment vaccine.